Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies.
Anastasia Stella PerpiniaNikolaos P E KadoglouMaria VardakaGeorgios GkortzolidisApostolos KaravidasTheodoros MarinakisChrysostomi PapachrysostomouPanagiotis MakaronisCharikleia VlachouMarina MantzouraniDimitrios FarmakisKonstantinos KonstantopoulosPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation.
Keyphrases
- left ventricular
- heart failure
- arterial hypertension
- end stage renal disease
- cardiac resynchronization therapy
- hypertrophic cardiomyopathy
- cardiovascular disease
- acute myocardial infarction
- ejection fraction
- aortic stenosis
- mitral valve
- drug induced
- healthcare
- newly diagnosed
- chronic kidney disease
- atrial fibrillation
- left atrial
- peritoneal dialysis
- oxidative stress
- acute myeloid leukemia
- risk factors
- type diabetes
- stem cells
- patient reported
- affordable care act
- aortic valve